Daan Gene002030.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Daan Gene (002030.SZ) trades at a negative P/E (-11.41x, due to a recent net loss), P/B of 1.11x, P/S of 11.90x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 16th percentile over the trailing 10Y window (vs. 49th percentile over 3Y); P/S sits at the 90th percentile over the trailing 10Y window (vs. 79th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 9th percentile within its industry and the 11th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Daan Gene operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 002030 · SZSE: 002030 · 002030
Want the full picture on whether Daan Gene (002030.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -11.41 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 1.11 | ||||||
| P/S (TTM) | 11.90 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |